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ABSTRACT The global coronavirus disease 2019 (COVID-19) pandemic has mobilized
efforts to develop vaccines and antibody-based therapeutics, including convalescent-
phase plasma therapy, that inhibit viral entry by inducing or transferring neutralizing
antibodies (nAbs) against the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) spike glycoprotein (CoV2-S). However, rigorous efficacy testing requires exten-
sive screening with live virus under onerous biosafety level 3 (BSL3) conditions, which
limits high-throughput screening of patient and vaccine sera. Myriad BSL2-compatible
surrogate virus neutralization assays (VNAs) have been developed to overcome this
barrier. Yet, there is marked variability between VNAs and how their results are pre-
sented, making intergroup comparisons difficult. To address these limitations, we
developed a standardized VNA using CoV2-S pseudotyped particles (CoV2pp) based
on vesicular stomatitis virus bearing the Renilla luciferase gene in place of its G glyco-
protein (VSVDG); this assay can be robustly produced at scale and generate accurate
neutralizing titers within 18h postinfection. Our standardized CoV2pp VNA showed a
strong positive correlation with CoV2-S enzyme-linked immunosorbent assay (ELISA)
results and live-virus neutralizations in confirmed convalescent-patient sera. Three in-
dependent groups subsequently validated our standardized CoV2pp VNA (n. 120).
Our data (i) show that absolute 50% inhibitory concentration (absIC50), absIC80, and
absIC90 values can be legitimately compared across diverse cohorts, (ii) highlight the
substantial but consistent variability in neutralization potency across these cohorts,
and (iii) support the use of the absIC80 as a more meaningful metric for assessing the
neutralization potency of a vaccine or convalescent-phase sera. Lastly, we used our
CoV2pp in a screen to identify ultrapermissive 293T clones that stably express ACE2 or
ACE2 plus TMPRSS2. When these are used in combination with our CoV2pp, we can
produce CoV2pp sufficient for 150,000 standardized VNAs/week.
IMPORTANCE Vaccines and antibody-based therapeutics like convalescent-phase plasma
therapy are premised upon inducing or transferring neutralizing antibodies that inhibit
SARS-CoV-2 entry into cells. Virus neutralization assays (VNAs) for measuring neutralizing
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antibody titers (NATs) are an essential part of determining vaccine or therapeutic effi-
cacy. However, such efficacy testing is limited by the inherent dangers of working with
the live virus, which requires specialized high-level biocontainment facilities. We there-
fore developed a standardized replication-defective pseudotyped particle system that
mimics the entry of live SARS-CoV-2. This tool allows for the safe and efficient measure-
ment of NATs, determination of other forms of entry inhibition, and thorough investiga-
tion of virus entry mechanisms. Four independent labs across the globe validated our
standardized VNA using diverse cohorts. We argue that a standardized and scalable
assay is necessary for meaningful comparisons of the myriad of vaccines and antibody-
based therapeutics becoming available. Our data provide generalizable metrics for
assessing their efficacy.
KEYWORDS COVID-19, SARS-CoV-2, convalescent-phase plasma, neutralizing
antibodies, viral neutralization assay
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, posi-tive-sense, single-stranded RNA (1ssRNA) virus from the family Coronaviridae. SARS-
CoV-2 is related to, but not derived from, SARS-CoV, which we will refer to as SARS-CoV-
1 for clarity. SARS-CoV-1 and SARS-CoV-2 belong to the genus Betacoronavirus and
group together as sarbecoviruses, a subgenus that also contains numerous bat “SARS-
like” CoVs (1). SARS-CoV-1 caused a limited epidemic of SARS from 2002 to 2004, infect-
ing ;8,000 people and killing 774 (2, 3). SARS-CoV-1 was ultimately contained and has
not reappeared. SARS-CoV-2 is the causative agent for coronavirus disease 2019 (COVID-
19). The Chinese government first reported a cluster of 40 cases of atypical pneumonia
(now known to be COVID-19) to the WHO on 30 December 2019. Since then, SARS-CoV-
2 has erupted into a global pandemic, resulting in tens of millions of cases and more
than a million deaths (4).
The emergence and spread of SARS-CoV-2 have required a global response to miti-
gate the fallout from the pandemic. As a result, the highest priorities for governments
around the world are prevention, treatment, and monitoring of infection and immunity
(5). Understanding and monitoring immune responses to SARS-CoV-2 are critical for the
development of antibody-based therapeutics and vaccines. Both are challenging to
study at the necessary scale due to the inherent danger of working with live virus and
because of limited access to high-level biosafety containment facilities (i.e., biosafety
level 3 [BSL3]). However, the development of pseudotyped viral particles capable of
recapitulating SARS-CoV-2 entry—without the dangers or limitations of working with
live virus—addresses these concerns. Many such pseudotype virus (PsV) systems based
on a lentivirus or vesicular stomatitis virus (VSV) backbone have been published (6–9).
These PsV systems have been used to understand and assess humoral immunity in
acute-phase and recovered COVID-19 patients and to screen for therapeutic entry inhib-
itors, such as small molecules, monoclonal antibodies, or convalescent-phase sera. Most
importantly, such a surrogate BSL2 virus neutralization assay (VNA) is needed to screen
for vaccine-induced responses in domestic animals and humans as the world rushes to
develop candidate vaccines against SARS-CoV2.
As of this writing, at least five SARS-CoV-2 vaccine developers have reported phase
I/II results involving over 1,700 participants (10–15). While each group claims promising
results, it is difficult to compare vaccine-induced immune responses between the vari-
ous vaccine platforms. This is not only due to a lack of a standardized reporting but
also due to a lack of standardized assays for reporting virus neutralization titers.
Furthermore, at least 16 studies have reported 350 patients receiving convalescent-
phase plasma therapy for COVID-19. Across all 16 plasma studies, some groups estab-
lish enzyme-linked immunosorbent assays (ELISAs) or live-virus neutralization thresh-
olds to screen donor plasma, while others do not report binding or neutralization data
(16–33). Notably, none of these studies report using a PsV VNA to screen donor plasma.
These discrepancies in screening methods/metrics limit the ability to compare across
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groups and make it difficult to draw conclusions about the quality/potency of antibody
transferred to the recipient (32, 33).
A standardized VNA that provides robust, high-throughput results (.100,000 infec-
tions/week), generates absolute virus neutralization titers (VNT), and is easily “kit-able”
due to its repeatability and ease of use would allow for meaningful comparisons across
different labs. In addition to helping down-select the myriad vaccine candidates, use of
a standardized VNA to report VNT in absolute units can crowd-source the immense
effort being expended by multiple labs across the globe to better understand the basis
of the marked variation in VNT seen in recovered COVID-19 patients (34, 35).
The SARS-CoV-2 spike glycoprotein (S) is embedded in the viral envelope and facili-
tates both receptor recognition and membrane fusion. SARS-CoV-2-S is 1,273 amino
acids in length and, as in other coronaviruses, is a trimeric class I fusion protein (36).
The S glycoprotein contains two subunits, the N-terminal S1 subunit and the C-termi-
nal S2 subunit. The S1 subunit contains the receptor-binding domain (RBD), which is
responsible for host receptor binding. The S2 subunit contains the transmembrane do-
main, cytoplasmic tail, and machinery necessary for fusion, notably the fusion peptide
and heptad repeats (37, 38). Angiotensin-converting enzyme 2 (ACE2), a cell surface
enzyme in a variety of tissues, facilitates the binding and entry of SARS-CoV-2 (39–41).
However, ACE2 alone is not sufficient for efficient entry into cells. While entry depends
on the S1 subunit binding ACE2, entry is further enhanced by proteolytic cleavage
between the S1/S2 and S29 subunits. For both SARS-CoV-1 and SARS-CoV-2, this cleav-
age-mediated activation of S-mediated entry is supported by the expression of cell-
associated proteases, like cathepsins or transmembrane protease serine 2 (TMPRSS2),
or the addition of exogenous proteases that mimic the various trypsin-like proteases
present in the extracellular lung milieu (39, 42–51). These proteases facilitate entry at
the cell surface or via an endosomal route in a cell type-dependent manner.
Extracellular proteases are thought to play a pathophysiogical role in the lung tissue
damage caused by unabated Middle East respiratory syndrome CoV (MERS-CoV), SARS-
CoV-1, and likely SARS-CoV-2 replication (49, 50). Thus, in order to represent SARS-CoV-
2 cell entry faithfully, a VNA must be sensitive not only to ACE2 binding but also to the
proteolytic activation of spike.
In addition to having a role in receptor binding and entry, S is the primary surface
glycoprotein and is the major target of the neutralizing antibody response (52–56).
Patients infected with SARS-CoV-2 typically seroconvert within 2 weeks of symptom
onset, with about half developing antibodies within 7 days (57–59). Antibody titers
appear to be durable at greater than 40 days postinfection (58), but in the case of
SARS-CoV-1, reductions in IgG-positive titers begin around 4 to 5months postinfection
and show a significant drop by 36months (60). Although there are reports of SARS-
CoV-2-infected individuals testing positive by reverse transcription-PCR (RT-PCR) weeks
after being confirmed as recovered by two consecutive negative tests, these are more
likely the result of false-negative results than of reinfection (61, 62). Multiple groups
have shown that fully recovered rhesus macaques previously infected with SARS-CoV-2
are refractory to reinfection, at least within 4 weeks of the primary challenge (63, 64).
However, a better understanding of the durability and efficacy of the neutralizing anti-
body response in patients previously infected with SARS-CoV-2 is of paramount impor-
tance. Not only do IgG titers wane in the case of SARS-CoV-1, but reinfection is possible
in other endemic human coronaviruses (HCoVs), such as 229E, NL63, and OC43, in as
little as a year (65–67). Whether the waning of neutralizing SARS-CoV-2 antibodies
impacts susceptibility to reinfection is an urgent question that needs to be answered
by longitudinal follow-up studies (68–71).
Humoral immune responses to the SARS-CoV-2-S protein are typically evaluated by
an ELISA and its many variants (chemiluminescence immunoassay [CLIA], lateral-flow
assay [LFA], etc.). These serological binding assays rightfully play a central role in deter-
mining patient antibody responses and can complement diagnostics and sero-epide-
miological studies, especially when combined with antibody subclass determination
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(IgM, IgA, and IgG) (72–74). Nonetheless, as many antibodies generated to the spike
protein bind but do not block virus entry (75–78), ELISA-based assays that detect titers
of spike-binding antibodies cannot always correlate perfectly with neutralizing anti-
body titers as measured by plaque reduction neutralization or microneutralization
(MN) tests (74, 79–82). Even a cleverly designed competitive ELISA set up to detect
antibodies that block the binding of the RBD to ACE2 (76, 83) cannot capture the uni-
verse of neutralizing antibodies targeted to a conformationally dynamic trimeric spike
on a virion (84, 85). The gold standard for detecting antiviral antibodies remains the vi-
rus neutralization assay. Assays that faithfully recapitulate entry of SARS-CoV-2 while
maximizing safety, speed, and scalability will be vital in the coming months and years.
They will enable monitoring of a patient’s neutralizing antibody response, the effica-
cies of vaccines and entry inhibitors, and the screening of convalescent-phase plasma
from recovered COVID-19 patients (57, 86).
In order to meet this need while maximizing safety, speed, and scalability, we gen-
erated SARS-CoV-2 pseudotyped viral particles (CoV2pp) by using vesicular stomatitis
virus bearing the Renilla luciferase gene in place of its G glycoprotein (VSVDG-rLuc).
This approach has been used safely by our group and others to study viruses that
would otherwise require significant biosafety constraints, including Ebola virus, Nipah
virus (NiV), and, most recently, SARS-CoV-2 (6, 8, 87–90). Here, we present a detailed
protocol for the production of CoV2pp, characterize the contributions of stable expres-
sion of ACE2 as well as endogenous or exogenous proteases on entry, and standardize
the production and performance characteristics of these CoV2pp for use in a robust
high-throughput VNA. We have sent out our standardized CoV2pp as ready-to-use
“out-of-the-box” VNAs, handling $1,000 infections/request, to multiple labs across
three continents. We show here the validation of our CoV2pp in a standardized
VNA by four independent groups spread across two continents using serum sam-
ples from geographically distinct and ethnically diverse cohorts. Lastly, we utilized
our standardized CoV2pp and VSV-Gpp in a screen to identify two ultrapermissive
293T cell clones that stably express either ACE2 alone or ACE2 and TMPRSS2. These
isogenic cell lines support SARS-CoV-2 entry via endocytic trafficking (i.e., 293T-
ACE2 cells for the “late” pathway) or via fusion at or near the cell surface (i.e., 293T-
ACE2/TMPRSS2 for the “early” pathway) (40, 45, 50, 91–93). These ultrapermissive
293T clones allow for use of unpurified virus supernatant from our standard virus
production batch, which can now provide for ;150,000 infections per week (96-
well format) with no further scale-up. In sum, we have generated a standardized,
scalable, high-throughput BSL2-compatible CoV2pp VNA that can provide robust
metrics (absolute 50% inhibitory concentration [absIC50], absIC80, absIC90) for mean-
ingful comparisons between labs.
RESULTS
Production of VSVDG-rLuc bearing SARS-CoV-2 spike glycoprotein. Our initial
objective was to produce SARS-CoV-2 PsV sufficient for $10,000 infections/week at an
;1:100 signal/noise ratio when the assay was performed in a 96-well format. We set-
tled on a VSV-based rather than a lentiviral PsV system, as lentiviruses are intrinsically
limited by their replication kinetics and particle production rate (104 to 106/ml for lenti-
viruses versus 107 to 109/ml for VSV without concentration). Additionally, one advant-
age of a VSV-based neutralization assay over a lentiviral PsV system is the potential to
use them in areas with high HIV prevalence without concerns that the assay may be
impacted by patients taking antiretroviral drugs. We optimized the production of our
VSVDG-rLuc pseudotyped viral particles (pp) bearing the SARS-CoV-2 spike glycopro-
tein as diagramed in Fig. 1A. A detailed production protocol is given in Text S1 in the
supplemental material. Notably, this protocol involves infecting producer cells at a low
multiplicity of infection (MOI) of stock VSVDG-G*, incubating producer cells with an
anti-VSV-G monoclonal antibody, and generating the pseudotyped particles in Opti-
MEM media. The first two measures effectively eliminated the background signal from
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residual VSV-G, while the last measure allowed for more cleavage of SARS-CoV-2pp in
producer cells (Fig. S1). While others have shown that truncating the cytoplasmic tail
of SARS-CoV-2-S is typically required for greater functional incorporation into heterol-
ogous viral cores (7, 9, 92, 93), we chose to optimize pseudotyping with full-length
SARS-CoV-2 spike. Cytoplasmic tail truncations in many other class I viral fusion pro-
teins, including other ACE2-using coronaviruses (HCoV NL63 and SARS-CoV-1), can
affect ectodomain conformation and function (94–103). Until such time that we gain a
fuller understanding of SARS-CoV-2 entry, we felt that it was necessary to have a surro-
gate assay that reflects the biology of the full-length virus spike protein.
Following the protocol detailed in Text S1, we produced BALDpp, NiV receptor
binding protein pp (NiV-RBPpp), CoV2pp, and VSV-Gpp using the VSVDG-rLuc reporter
backbone and determined their titers on Vero-CCL81 cells (Fig. 1B). High-background
problems have resulted in low signal/noise ratios when using VSV-based PsV, especially
for viral envelope proteins that do not mediate efficient entry. Here, we used two dif-
ferent negative controls, BALDpp and NiV-RBP, to show that we resolved the back-
ground issue. BALDpp lacks any surface glycoprotein, while NiV-RBPpp incorporates
the NiV-RBP, which binds to broadly expressed ephrin-B2 with subnanomolar affinity
(88, 104). However, the NiV fusion (NiV-F) glycoprotein necessary for viral entry is
FIG 1 Production of VSVDG-rLuc bearing the SARS-CoV-2 spike glycoprotein. (A) Overview of VSVDG-rLuc-pseudotyped particles bearing CoV-2 spike (top),
with annotated spike glycoprotein domains and cleavage sites (bottom). As mentioned in the text, we refer to SARS-CoV as SARS-CoV-1 for greater clarity.
(B) The titers of VSV-DG[Rluc]-pseudotyped particles (VSVpp) bearing the Nipah virus receptor binding protein alone (NiV-RBPpp), SARS-CoV-2-S (CoV2pp),
or VSV-G (VSV-Gpp) were determined on Vero-CCL81 cells using a 10-fold serial dilution. Symbols represent the means 6 standard errors of the means
(SEM) (error bars) from each titration performed in technical triplicates. (C) Expression of the indicated viral glycoproteins on producer cells and their
incorporation into VSVpp. Western blots performed as described in Materials and Methods using anti-S1- or anti-S2-specific antibodies. (D) CoV2pp entry is
inhibited by the soluble receptor binding domain (sRBD) derived from SARS-CoV-2-S. CoV2pp and VSV-Gpp infection of Vero-CCL81 cells was performed as
described for panel B in the presence of the indicated amounts of sRBD. Neutralization curves were generated by fitting data points using a variable slope,
a 4-parameter logistics regression curve (robust fitting method). The last point (no sRBD) was fixed to represent 100% maximal infection. The results of
each replicate from an experiment performed in duplicate are shown. The calculated IC50 for sRBD neutralization of CoV2pp is 4.65mg/ml.
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absent. NiV-RBPpp without NiV-F should not fuse and effectively serves as a stricter
and complementary negative control. Under the conditions shown, neither BALDpp
nor NiV-RBPpp gives any background even at the highest concentration of virus par-
ticles used.
These constructs were used to infect Vero-CCL81 cells, and as expected, we
observed an average of ,500 relative luciferase units (RLUs) of entry with our BALDpp
and NiV-RBPpp negative controls. These levels of entry were comparable to the “cells
only” signal, providing confidence in any infection signals 10-fold over background.
Undiluted CoV2pp entry resulted in luciferase values of over 50,000 RLUs, greater than
100-fold over background BALDpp signals (Fig. 1B). VSV-Gpp gave infectivity several
logs higher, as expected. Western blots of the producer cells demonstrated effective
expression of cleaved SARS-CoV-2 spike glycoproteins (Fig. 1C, left panel). Cleaved
CoV-2 spike products (S1, S2, and S29) all appear to be incorporated into the VSVDG
pseudotyped particles (Fig. 1C, right panel). To ensure that entry of CoV2pp is SARS-
CoV-2 spike mediated, we show that the homologous soluble receptor binding domain
(sRBD) of spike competitively inhibits our CoV2pp (Fig. 1D).
CoV2pp entry is enhanced by trypsin treatment and spinoculation. Next, we
sought to enhance the relative signal of our CoV2pp infections, which effectively
increases the number of infections that we can provide or perform per batch of
CoV2pp. Trypsin treatment is reported to enhance SARS-CoV-1 and SARS-CoV-2 entry
(39, 45). Thus, we treated CoV2pp stocks with the indicated range of trypsin concentra-
tions for 15min at room temperature (Fig. 2A). In order to mitigate the effects of tryp-
sin-dependent cytotoxicity, we added 625mg/ml of soybean trypsin inhibitor (SBTI) to
all samples before titrating the trypsin-treated CoV2pp onto Vero-CCL81 cells. CoV2pp
treated with the highest concentration of trypsin (625mg/ml) resulted in an ;100-fold
FIG 2 CoV2pp entry is enhanced by trypsin treatment. (A) Optimizing trypsin treatment conditions. Supernatants containing CoV2pp were trypsin treated
at the indicated concentrations for 15min at room temperature prior to the addition of 625mg/ml of SBTI. The titers of these particles were then
determined on Vero-CCL81 cells in technical triplicates. Data are shown as means 6 SEM. (B) Dilution in serum-free media (SFM, DMEM only) provides the
highest signal/noise ratio for trypsin-treated CoV2pp entry. Particles were diluted 1:10 in Opti-MEM, SFM, or DMEMplus 10% FBS prior to infection of Vero-
CCL81 cells and spinoculation as described in the legend of Fig. 1D. Cells infected without spinoculation show approximately 3-lower signal/noise ratios
(see Fig. S2 in the supplemental material). (C) Addition of soybean trypsin inhibitor at the time of infection reduces trypsin-treated particle entry. This assay
was performed in technical triplicates for two independent experiments. Shown are the combined results, with error bars indicating SEM and ****
indicating a P value of ,0.0001. (D) Schematic showing an overall view of how protease priming and SBTI treatment works to enhance CoV2pp entry.
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enhancement of entry (Fig. 2A), but this trypsin-dependent enhancement was appa-
rent only when we compared entries of undiluted trypsin-treated CoV2pp. We
observed a .50-fold reduction in entry (RLUs) after a 10-fold serial dilution, which nul-
lified any entry enhancement effects of trypsin. Indeed, the role of trypsin in enhancing
SARS-CoV-2 entry has not been fully determined. Trypsin may act to prime CoV2pp to
facilitate better entry upon spike-receptor interactions and/or assist to proteolytically
activate spike protein at or after receptor binding (50). We hypothesized that the
remaining uninhibited trypsin-dependent effect, which must be present at the highest
trypsin concentration, was inadvertently neutralized by diluting the trypsin-treated
CoV2pp in Dulbecco’s modified Eagle medium (DMEM) plus 10% fetal bovine serum
(FBS), which is the standard infection medium for titrating CoV2pp. To test this hypoth-
esis, we diluted CoV2pp and trypsin-treated CoV2pp 1:10 under three different me-
dium conditions before infecting Vero-CCL81 cells. For trypsin-treated CoV2pp, dilution
in DMEM alone (serum-free medium [SFM]) produced the highest signal/noise ratio,
almost 1,000-fold over that of BALDpp (Fig. 2B). As a result, we chose CoV2pp treated
with 625mg/ml of TPCK (tosylsulfonyl phenylalanyl chloromethyl ketone)-treated tryp-
sin and then 625mg/ml of SBTI diluted in SFM as our standard treatment condition.
Furthermore, spinoculation at 1,250 rpm for 1 h enhanced entry 3- to 5-fold (compare
signal/noise ratios in Fig. 2B to those in Fig. S2).
Our above hypothesis suggests that the uninhibited trypsin-dependent enhancing
effect acts at the point of infection when CoV2pp interact with the host cell receptor.
To investigate further, we spiked additional SBTI onto cells at the time of infection
using particles produced under the standard treatment condition, as above. We found
that additional SBTI ($25mg/ml) added directly to cells at the point of infection was
able to inhibit trypsin-dependent entry enhancement (Fig. 2C). The data suggest that
some trypsin was not inhibited by the first 625mg/ml of SBTI and that enough
remained to enhance entry at the point of infection (Fig. 2D).
Entry of CoV2pp is independently enhanced by stable expression of ACE2 and
TMPRSS2 in cells already permissive for SARS-CoV-2 entry and replication. To fur-
ther characterize the determinants of CoV2pp entry, we generated Vero-CCL81 cell
lines stably expressing human ACE2 or human TMPRSS2. Vero-CCL81 cells are already
highly permissive for SARS-CoV-2 entry and replication. We infected the indicated cells
with CoV2pp or trypsin-treated CoV2pp diluted in serum-free medium (standard treat-
ment) and observed enhanced entry in both stable cell lines (Fig. 3A). However, the
entry enhancement of trypsin-treated CoV2pp in Vero-CCL81 TMPRSS2-overexpressing
cells was subdued relative to that in untreated CoV2pp. This suggests that the
FIG 3 Trypsin-treated CoV2pp depend on ACE2 and TMPRSS2 for entry. (A) Parental and TMPRSS2- or ACE2-
transduced Vero-CCL81 cells were infected with the indicated pseudotyped viruses. All particles were diluted in
serum-free media in order to be within the linear range for the assay. Normalized infectivity data are presented
as fold values over those for Vero-CCL81 WT cells for the various VSVpp shown. VSV-Gpp served as an internal
control for the intrinsic permissiveness of various cell lines to VSV-mediated gene expression. Data are
presented as means 6 SEM from two independent experiments done in technical triplicates. *, P , 0.05; **,
P , 0.01; ****, P , 0.0001. (B) Western blot of wild-type and transduced Vero CCL81 cells. The numbers below
each column show that the relative ACE2 abundance was measured by densitometry and normalized as
described in Materials and Methods.
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presence of exogenous trypsin during CoV2pp entry can substitute, in part, for the role
played by cell surface TMPRSS2, an endogenous protease known to facilitate entry into
physiologically relevant cell types in vivo (40). Figure 3B shows that the relationship
between ACE2 and TMPRSS2 expression—with regard to their effect on enhancing
SARS-CoV-2 spike-mediated entry—is not straightforward. As ACE2 itself is a substrate
for TMPRSS2, the right stoichiometry of receptor/protease expression appears to be
the main driver of entry efficiency rather than the absolute expression of one or the
other. This issue will be further examined in the last section.
Standardizing the parameters that impact our CoV2pp-based virus neutralization
assay. Having established that exogenous trypsin can serve as a physiologically rele-
vant substitute for endogenous proteases known to enhance entry of CoV2pp, such as
TMPRSS2, we sought to characterize the parameters that might affect the performance
our CoV2pp VNA. Conditions tested included heat inactivation of sera and the infection
medium used to dilute human serum samples. We used representative spike ELISA-
positive or -negative sera to serve as positive and negative controls, respectively.
When sera were first diluted in SFM, we observed that negative sera can have alarming
amounts of neutralizing activity that appear specific for CoV2pp, as the same sera did
not neutralize VSV-Gpp entry (compare Fig. S3A with Fig. S3B, right panel). This
CoV2pp serum-neutralizing factor is somewhat reduced but not completely diminished
by heat inactivation for 1 h at 56°C. Notably, the effect of this neutralizing factor from
negative sera was preempted by diluting the trypsin-treated CoV2pp in DMEM con-
taining 10% FBS (Fig. S3B). Importantly, recombinant sRBD neutralization was not
affected by the dilution of CoV2pp in SFM or DMEMplus 10% FBS (Fig. S3C). The nature
of the factor that appears to inhibit spike-mediated entry is the subject of a concurrent
manuscript in submission (see Discussion) (105). Regardless, for standardizing our
CoV2pp-based VNA, all subsequent patient sera were heat inactivated for at least 30
min prior to use and serially diluted in DMEMplus 10% FBS, which also served as our
infection medium. Despite our data from Fig. 2 implicating a trypsin inhibitor-like activ-
ity in FBS, the marked inhibition of CoV2pp entry by seronegative human sera is a
greater limiting factor that prevents the robust determination of true SARS-CoV-2 neu-
tralizing antibody (nAb) titers. To achieve the same signal/noise ratio while performing
our VNA in the presence of 10% FBS, we increased the concentration of CoV2pp used
per infection.
Performance characteristics of our standardized CoV2pp virus neutralization
assay. An initial set of sera for validation of CoV2pp VNA was generously provided by
Florian Krammer. These sera were screened according to a previously described two-
stage ELISA protocol in which 1:50 dilutions of patient sera were first screened for reac-
tivity against the sRBD. Subsequently, the presumptive RBD-positive patient sera were
used to assess reactivity to the trimer-stabilized ectodomain of spike at five different
dilutions (1:80, 1:160, 1:320, 1:960, and 1:2,880) (73, 106). These samples were used for
neutralization studies with CoV2pp (Fig. 4A and B). From the 36 patient sera tested, 6
were found to be negative for SARS-CoV-2 spike binding in the ELISA described above.
All of those 6 serum samples also showed no neutralization of CoV2pp. The remaining
30 spike-positive sera had 50% neutralizing titers that span 2 orders of magnitude
(Fig. 4B, 160 to 10,240). For a more quantitative assessment of the correlation of our
assay to the other standards in the field, we compared the nAb titers as determined by
our CoV2pp VNA to both spike binding activity and live-virus microneutralization (MN)
titers for identical serum samples. We determined the total IgG and IgM spike binding
activity (ELISA area under the concentration-time curve [AUC], as described in
Materials and Methods) of a representative subset of 15 serum samples and compared
them with their reciprocal absIC50 and absIC80 values, calculated from the CoV2pp neu-
tralization curves (Fig. 4A), as described in Materials and Methods. Spike binding anti-
bodies (IgG plus IgM ELISA AUC) demonstrated a significant, positive correlation with
nAb titers, as determined by our CoV2pp VNA (Fig. 4C, green circles). Moreover, these
nAb titers against CoV2pp also correlated well with live-virus MN titers (MN absIC50,
MN absIC80) (Fig. 4C, brown triangles). Full neutralization curves for the MN titers are
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shown in Fig. S4. absIC80 appeared to be a more stringent measure of nAb activity, as
some sera that have respectable MN absIC50 titers never achieve an absIC80 (Fig. 4C,
bottom graph, brown triangles on the x axis, and Fig. S4). This is due in part to the dif-
ference in the dynamic ranges between a luciferase-based assay ($3 logs RLUs) and an
MN assay (;1.5-log optical density [OD] values corresponding to the amount of viral
protein detected). The larger dynamic range of the CoV2pp VNA was thus more able to
resolve the serum samples that can reach their respective absIC80 values. Notably, we
find that serum samples with potent absIC50 titers do not always display potent absIC80
values (Fig. 4D).
Independent validation of our CoV2pp VNA with geographically distinct and
ethnically diverse COVID-19 patient cohorts. To assess the robustness of our stand-
ardized CoV2pp VNA, we produced and distributed the CoV2pp to many labs who
have requested our assay for use in various screens for nAbs. Here, we analyze and
present the raw virus neutralization data provided to us by three independent groups
at the Icahn School of Medicine at Mount Sinai (ISMMS), at the Louisiana State
University Health Sciences Center Shreveport (LSUHS), and in Argentina (COVIDAR). In
serum or plasma neutralization studies performed in these independent labs, these
groups also observed similar absIC50, absIC80, and absIC90 distributions. The LSUHS and
ISMMS group 2 (ISMMS-2) cohorts represent data from 25 and 28 seropositive as well
as 10 and 11 seronegative samples, respectively, while the COVIDAR consortium
assessed neutralization from an initial set of 13 seropositive patient samples. For clarity,
an analysis of their neutralization curves is presented as heatmaps in Fig. 5A, similar to
FIG 4 CoV2pp viral neutralization assay and absIC50/absIC80 values versus those after spike binding of patient sera. (A) Thirty-six patient sera screened for
CoV2pp neutralization. CoV2pp were used to infect Vero-CCL81 cells in the presence of a 4-fold serial dilution of patient sera, as described in Materials and
Methods. Samples in light purple do not neutralize CoV2pp. Neutralization curves were fit using a variable-slope, 4-parameter logistics regression curve
with a robust fitting method. (B) The same 36 samples are shown as a neutralization heat map, which was generated in R as described in Materials and
Methods. Here, red represents complete neutralization, and blue represents no neutralization. Samples are sorted by the average from the first four
dilutions, with the most neutralizing samples on the left. (C) Correlation of CoV2pp neutralization titers to spike binding (ELISA AUC, green circles) and live-
virus microneutralization (MN, brown triangles) activity. The absolute IC50 (absIC50, top) and IC80 (absIC80, bottom) for CoV2pp neutralizations and live-virus
MNs were calculated in R using a 4-parameter logistic regression model as described in Materials and Methods. Presented are the added IgG and IgM
ELISA AUCs. AUC determinations and live-virus neutralizations were performed as described in Materials and Methods. Presented are the r and P values
from a simple linear regression. (D) Positive serum samples and their CoV2pp reciprocal absIC50 (top) and absIC80 (bottom) values. The IC50 graph is colored
and ordered to display samples with low, average, or high IC50s as blue, gray, or red circles, respectively. The IC80 graph below retains the coloring from
the IC50 graph, but the samples are now ordered from left to right to show samples with the lowest to highest IC80 values. Tukey box and whisker plots
show medians with interquartile ranges (IQR) and whiskers extending to 1.5 the IQR. All points outside that range are depicted.
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what is shown in Fig. 4B. Full neutralization curves for each cohort are shown in
Fig. S4.
The seronegative control samples from all groups revealed no CoV2pp neutraliza-
tion. Rare, but notable, seropositive samples from LSUHS also showed no neutraliza-
tion (Fig. 5A, LSUHS). ISMMS-2 performed its analysis on confirmed convalescent-phase
plasma donors (32). While all donors had detectable nAb titers, their titers were highly
varied and ranged across 2 to 3 logs. absIC80s were calculated for all samples shown,
and we observed a moderate, but significant, positive correlation between various
spike ELISA metrics and absIC80s (Fig. 5B).
Aggregated reciprocal absIC80s from all three external labs as well as our own are
shown in Fig. 5C. In total, we analyzed absIC80s from 89 individuals across four groups.
The descriptive statistics from this aggregated data set reveals reciprocal absIC80s in a
25th percentile of 68.5, a median of 170.8, and a 75th percentile of 343.4. Descriptive
statistics for reciprocal absIC50 and absIC90 values were also calculated and are
reported in Table S1. Using the absIC80 descriptive statistics above and the ELISA
endpoint titers from our initial 36 serum samples, we observe that 0% of the sam-
ples displaying an ELISA endpoint titer of 320 have an absIC50 greater than the me-
dian IC50. Perhaps not surprisingly, over 90% of samples with ELISA endpoints of
2,880 have IC50s at or beyond the 75th percentile (Table 1; represented graphically
in Fig. S5). Although the absIC80 also generally follows this trend, we once again
note differences in ranked order of absIC50 and absIC80 values calculated for all se-
rum samples. This difference is more pronounced when comparing the absIC50 and
absIC90 graphs, further highlighting the need for a neutralization assay with a broad
dynamic range (Fig. S7, left panel). Additionally, the samples from each of the 4
groups show no statistical difference when absIC50, absIC80, or absIC90 calculations
are compared (Fig. S7, right panel). All together, these data support the robustness
FIG 5 CoV2pp viral neutralization assay validated against patient sera by external groups. (A) Patient serum neutralization of CoV2pp for 88 samples run
by three different independent groups. This is visualized as in Fig. 4B, where red represents complete neutralization and blue represents no neutralization.
(B) Correlations of CoV2pp reciprocal absIC80s to those of spike ELISAs. The absIC80 was calculated as described in the legend of Fig. 4C. For LSUHS ELISAs,
the spike ectodomain was used and sera were diluted to a 1:100 dilution. For the COVIDAR ELISAs, a mixture of the sRBD and spike was utilized as
previously described (116), and the AUC was calculated as described in Materials and Methods. (C) Summary absIC80s of 89 positive serum CoV2pp
neutralizations. Samples from all 4 groups are depicted on the x axis. The absIC80 was calculated as described in the legend of Fig. 4C, and Tukey box and
whisker plots are shown as described in the legend of Fig. 4D.
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of our CoV2pp VNA and suggest that the absIC80 is a more stringent and meaning-
ful measure of nAb titers.
Ultrapermissive 293T-ACE2 and 293T-ACE+TMPRSS2 clones allow for use of
CoV2pp in VNA at scale. Although our standardized VNA appears robust, the require-
ment for exogenous trypsin and spinoculation to achieve the optimal signal/noise ratio
limits the scalability of our VNA. Therefore, we used our untreated CoV2pp to screen
for ultrapermissive cell lines that would allow for our CoV2pp VNA to be performed
with dilutions of virus supernatant without any trypsin treatment, virus purification, or
spinoculation.
We generated three different 293T cell lines stably expressing ACE2 and/or TMPRSS2
via lentiviral transduction. We then infected these cells with CoV2pp. Increased
expression of TMPRSS2 alone (293T-TMPRSS2) did not significantly improve entry
(Fig. 6A), likely due to the low to undetectable ACE2 expression levels (Fig. 6B, lanes
1 and 3). However, expression of ACE2 significantly increased the entry of CoV2pp,
which was further increased in 293T-ACE2 plus TMPRSS2 (293T-ACE21TMPRSS2)
TABLE 1 Comparison of ELISA endpoint titers to CoV2pp neutralizationa
ELISA
endpoint













320 7/11 (63.6) 0/11 (0) 0/11 (0) 4/11 (36.4) 1/11 (9.1) 0/11 (0)
960 6/8 (75) 4/8 (50) 0/8 (0) 7/8 (87.5) 4/8 (50) 1/8 (12.5)
2,880 11/11 (100) 11/11 (100) 10/11 (90.9) 11/11 (100) 10/11 (90.9) 5/11 (45.5)
aPresented are the clinical lab ELISA endpoint titers from samples discussed in Fig. 4A. Descriptive statistics were
generated in PRISM using data presented in Fig. 5C. Values highlighted in bold are of interest and are discussed
further in Results.
FIG 6 293T cells stably transduced with ACE2 and TMPRSS2 (293T-ACE21TMPRSS2) are ultrapermissive for SARS-CoV-2pp infection. (A) Infection of 293T
cell lines transduced to stably express TMPRSS2, ACE2, or both. Cell lines were generated as described in Materials and Methods. A single dilution of
particles was used to infect cells prior to spinoculation as described in Materials and Methods. Infections were done in technical triplicates. Presented are
the aggregated results from two independent replicates, and error bars show SEM. For statistics, ns indicates not significant, ** indicates a P value of
,0.01, and **** indicates a P value of ,0.0001. (B) Western blot of ACE2 expression in 293T cell lines. Blotting was performed as described in Materials and
Methods, and the values below the columns represent the relative abundances of ACE2. (C) Normalized CoV2pp entry into single-cell clones. Entry was
normalized to that of the wild-type parental cell line and further normalized to VSV-G entry. Presented are the averages from one experiment in technical
triplicates. Error bars show the medians and interquartile ranges. Raw entry data for each cell clone are shown in Fig. S8A. (D) Entry inhibition of CoV2pp
by nafamostat mesylate, a serine protease inhibitor. Nafamostat was mixed with CoV2pp (left panel) or VSV-Gpp (right panel) prior to addition to cells.
Shown are the results from one experiment in technical triplicates. Data are presented as described in the legend of Fig. 4A, and error bars show SEM.
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cells, suggesting the synergistic activity of TMPRSS2 and ACE2 (Fig. 6A). Western blot
analysis confirmed the increased expression of ACE2 in the singly and doubly trans-
duced 293T cells (Fig. 6B). Additionally, increased expression of both ACE2 and
TMPRSS2 was confirmed by quantitative PCR (qPCR) (Fig. S8B). Interestingly, ACE2
expression appeared to be decreased by .50% in 293T-ACE21TMPRSS2 cells relative
to that in 293T-ACE2 cells. These observations highlight the complex roles that recep-
tor binding and protease activation play in SARS-CoV-2 entry, especially since ACE2 is
a known substrate for TMPRSS2 (107) and TMPRSS2 is also known to undergo autoca-
talytic cleavage (108).
Given how TMPRSS2 can enhance ACE2-dependent virus entry in a nonlinear fash-
ion, we used BALDpp, CoV2pp, and VSV-Gpp to screen 19 single-cell clones derived
from 293T-ACE2, 293T-ACE21TMPRSS2, or Vero-ACE2 bulk-transduced cells. The last
(Fig. 3) served as an additional control in a naturally permissive cell line for SARS-CoV-2
entry and replication. All three bulk-transduced cell lines resulted in significant
increases in entry levels of CoV2pp relative to those of the parental 293T and Vero
CCL81 cells (Fig. S8 and Fig. 6C). However, only a subset of the single-cell clones per-
formed better than bulk-transduced cells. This is especially notable in single-cell clones
derived from 293T-ACE21TMPRSS2 parental cells, of which only two of eight single-
cell clones showed greater entry than the bulk-transduced cells (Fig. 6C). One particu-
lar clone, F8-2 (Fig. 6C), showed a nearly 10-fold increase in CoV2pp entry relative to
that of the bulk-transduced cells. Using F8-2 to titer untreated CoV2pp without spino-
culation, we observed a dramatic increase in signal/noise ratios relative to that of wild-
type Vero-CCL81 (Vero-CCL81 WT) cells and even the most permissive 293T-ACE2
clone, 5-7 (Fig. S8C), such that RLU signals were consistently 100- to 200-fold over those
of BALDpp even at a 1:50 dilution. TMPRSS2 was determined to be the main driver of
this entry enhancement in the F8-2 cells, as treatment with nafamostat, a serine protease
inhibitor, potently inhibited entry. However, this entry inhibition plateaued at 90% of
maximal infection, and the remaining 10% is nearly equivalent to the raw RLU values
seen with bulk 293Ts stably expressing ACE2 alone (Fig. 6D and Fig. S8B), suggesting a
TMPRSS2-independent mechanism of entry. Entry into 293T-ACE2 cells was not inhibited
by nafamostat, once again highlighting that CoV2pp can enter by both the early and
late entry pathways that have differential protease requirements.
Diverse cell lines maintain similar kinetics in CoV2pp viral neutralization
assays. We identified serum samples from 15 patients shown in Fig. 4A and placed
them into three tiers: negative for CoV2pp neutralization (negative), weakly positive
for CoV2pp neutralization (low positive), or strongly positive for CoV2pp neutralization
(high positive) (Fig. 7A). We then pooled equal volumes of each set of samples and per-
formed CoV2pp neutralization assays on Vero-CCL81 WT, 293T-ACE2 clone 5-7, and
293T-ACE21TMPRSS2 bulk-transduced cells and the 293T-ACE21TMPRSS2 clone F8-2.
We demonstrated that even in the case of various levels of ACE2 and TMPRSS2 expres-
sion, CoV2pp neutralization assays show consistent patterns of neutralization, exhibit-
ing the robust nature of the assay in tandem with its sensitivity in detecting relative
differences in neutralizing titers (Fig. 7B). Patterns of neutralization as well as the calcu-
lated absIC50 and absIC80 reveal a large dynamic range between low- and high-neutrali-
zation patient sera across cell lines (Fig. 7B).
DISCUSSION
Here, we present detailed and optimized protocols for producing VSVDG-pseudo-
typed viral particles bearing SARS-CoV-2 spike protein. These CoV2pp recapitulate the
SARS-CoV-2 entry requirement for ACE2 expression on the host cell and enhanced
infectivity in the presence of activating proteases, such as trypsin and/or TMPRSS2, in
both 293T and Vero cells. Evidence from our original standard condition suggested
that only a minor fraction of the trypsin added was required, and this trypsin acted at
the level of receptor binding on the host cell (Fig. 2C and D). Due to the observed
effect of trypsin at the point of infection, we hypothesize that interaction with a cellu-
lar factor, likely ACE2, induces conformational changes necessary for further protease-
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mediated activation, likely at the S29 cleavage site of SARS-CoV-2 spike. Moreover, in a
competitive inhibition assay, entry by the trypsin-treated CoV2pp was successfully
inhibited by the sRBD. This faithful recapitulation of the entry processes previously
described for SARS-CoV-1 and SARS-CoV-2 suggests that trypsin-treated CoV2pp repre-
sent a biologically relevant system for identifying cells that support SARS-CoV-2 entry
and for screening for entry inhibitors, especially neutralizing antibodies or patient sera.
Prior to the use of trypsin-treated CoV2pp for neutralization experiments, we
assessed how heat inactivation of sera and different cell media affect neutralization.
Here, we report detectable neutralization by negative patient sera, which was previ-
ously reported for mouse and human sera by Nie et al. (8) However, it is unclear
whether the sera used by Nie et al. were heat inactivated. Our observations also
raise questions concerning the role that the previously mentioned heat-labile se-
rum factor might play in vivo. We have shown that the CoV2pp VNA displays high
sensitivity to the inhibition of protease-mediated entry enhancement by human se-
rum, FBS, SBTI, and even nafamostat when the protease in question is TMPRSS2.
The inhibitory potential of human serum implies a role that serum factors may play
in SARS-CoV-2 pathogenicity, tissue restriction, and systemic spread in previously
SARS-CoV-2-naive patients (105). These findings led to the establishment of heat
inactivation of sera and use of DMEM plus 10% FBS as conditions for trypsin-treated
CoV2pp neutralization experiments. When used for viral neutralization assays with
patient sera, the absIC50/absIC80 against CoV2pp correlated strongly with the results
of full-length spike ELISAs and live-virus microneutralization titers. Moreover, we
have produced several batches of our CoV2pp and shipped them (along with Vero-
CCL81 cells) to many other groups as an out-of-the-box neutralization assay. The
first three groups to receive these particles and who volunteered their data have
successfully screened patient sera with our assay and observed moderate but sig-
nificant correlations with the results of spike ELISAs.
While ELISAs provide valuable information about epitopes recognized by individual
samples and antibody quantities, functional studies allow for more in-depth analyses
of neutralization potential. Notably, RBD-binding antibodies, particularly those
FIG 7 Ultrapermissive 293T-ACE21TMPRSS2 cell clones retain the same phenotypic sensitivity to convalescent COVID-19 sera. (A) Selection of pooled
serum samples. Results from Fig. 4A are reproduced here for the reader’s convenience. Presented is the subset of samples that were pooled for use in
VNAs in the adjacent panel. (B) Vero CCL81 and transduced 293T cells were used for VNAs. Sera previously shown to be negative, weakly positive, or
strongly positive for CoV2pp neutralization were selected to be pooled in equal volumes. These were subsequently used for VNAs, which were performed
and presented as described in the legend of Fig. 4A. Notably, these VNAs were performed in the absence of exogenous trypsin or spinoculation.
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inhibiting ACE2, have received a large amount of attention. To identify antibodies ca-
pable of preventing receptor binding, many groups have developed competition
ELISAs (83), which may serve as a closer surrogate for virus-neutralizing titers.
However, recent studies identifying non-RBD binding—yet still neutralizing—antibod-
ies lend insight into novel neutralization mechanisms and further highlight the impor-
tance of functional neutralization assays (84, 85). Moreover, our standardized CoV2pp
VNA has a large dynamic range that can generate robust neutralization curves, which
allows for the calculations of more stringent metrics, such as absIC50/absIC80 values.
absIC50/absIC80 values give a more meaningful description of the neutralization
potential, describing differences that may account for variance in clinical potency
(109) of a given serum sample, as many patient sera (and potentially vaccine sera)
may not even achieve an absIC80. The importance of measuring different thresholds
for inhibitory potency has been shown by previous work comparing monoclonal
antibodies alone and in combination against different epitopes in order to identify
optimal antibody combinations for neutralization (110). Reporting such standar-
dized metrics will allow more meaningful comparisons of vaccine-elicited humoral
responses and the neutralization potential of convalescent-phase sera, especially
when the latter is used for convalescent-phase plasma therapy. Additionally, we uti-
lized soluble RBD-Fc for neutralizations in two independent labs (Fig. S6) and report
comparable values for absolute IC50s and IC80s. Indeed, the almost-identical IC80 val-
ues reinforce our proposal that the absIC80 is a more accurate and reproducible
metric of neutralization potency. The use of standardized metrics and comparisons
to standardized samples is of particular importance given the widely varied ratios
of spike ELISA binding values and neutralizing antibody titers in comparisons of
patients infected by SARS-CoV-2 and patients receiving vaccines for SARS-CoV-2
(13).
Early reports of convalescent-phase serum therapies show a tolerable safety profile
and modest benefits from this therapeutic approach (17, 19, 20, 29, 31–33). However,
many of these trials consider only ELISA neutralization titers and utilize extremely var-
ied ELISA endpoint titers, from not reported/available to titers ranging from 1:40 to
.1:1,350. Interestingly, one pre-peer-reviewed study incorporated functional neutrali-
zation studies by utilizing trypsin-treated live virus to screen for sera with .1:80 micro-
neutralization titers on Vero E6 cells (33). Given the wide variance in ELISA titers as well
as in virus neutralization titers, we believe that convalescent-phase plasma therapy will
be enhanced if patient sera are functionally screened and limited to only those display-
ing potent neutralization titers. This will have the benefit of transfusing patients only
with convalescent-phase sera that have a strong likelihood of substantial in vivo inhibi-
tory potential, which is of particular importance given the volumes transfused relative
to a patient’s total blood volume. Given our results, a reasonable threshold might be a
VNA-derived reciprocal absIC80 of$343.3 (i.e., $75th percentile).
Lastly, we utilize the CoV2pp system to screen 19 single-cell clones and identify two
single-cell clones of interest. These clones (293T-ACE2 clone 5-7 and 293T-ACE21TMPRSS2
clone F8-2) both support effective viral entry in the absence of trypsin and spinocu-
lation and can be used for scaling up viral neutralization assays. The ultrapermissive
293T-ACE21TMPRSS2 F8-2 clone in particular can support the use of a standardized
VNA at the scale needed for screening entry inhibitors, vaccine samples, donor
plasma, etc. Our standardized CoV2pp production lot from a single lab, 30 10-cm
dishes, was sufficient for ;12,000 infections/week when the assay was performed in
a 96-well format. Trypsin-treated CoV2pp (diluted 1:4) gives a 100:1 signal/noise ra-
tio when performed in a 100-ml infection volume on Vero-CCL81 cells with spinocu-
lation. Using the ultrapermissive F8-2 clone, a 1:50 dilution gives a similar signal/
noise ratio without any trypsin treatment or spinoculation. Thus, our weekly produc-
tion lot becomes sufficient now for ;150,000 infections/week, which is enough for
generating full neutralization curves for ;4,600 to ;6,200 samples (assuming an 8-
point dilution series performed in quadruplicates or triplicates, respectively). With
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this, the optimized system utilizes CoV2pp to infect 293T F8-2 clones, which
removes the reliance on spinoculation or the addition of exogenous trypsin and will
enable the user to have a high dynamic range. Moreover, this system allows for the
detection of neutralization by both convalescent-phase plasma and TMPRSS2
inhibition.
Several recently described systems, including VSV encoding the SARS-CoV-2 spike
gene (9, 112) and lentiviruses pseudotyped to bear the spike protein (113), are capable
of serving as surrogate assays for assessing viral neutralization by patient sera or mono-
clonal antibodies. The replication-competent VSV system is attractive but still relies on a
truncated spike. We have not been able to rescue one with the full-length tail, even in
our F8-2 clone, although we could rescue multiple VSVs bearing various betacoro-
navirus spikes (all with truncated tails). Nonetheless, our standardized CoV2pp
based on the VSVDG system presents many advantages, including safety, ease and
speed of use, identity to full-length SARS-CoV-2 spike, versatility for studying spike
mutants, and a large dynamic range. First, the viral genome used in this system
lacks a viral glycoprotein, which limits the virus to single-cycle replication and miti-
gates concerns about viral spread. Next, because of the efficient replication of VSV,
this system can be used to further interrogate SARS-CoV-2 entry in primary cells
and allows for the detection of Renilla luciferase (or the desired reporter gene)
within 12 to 18 h postinfection. Additionally, the VSVDG system presented here rep-
resents viral entry in the absence of mutations or truncations for enhanced fusoge-
nicity and/or entry dynamics. Lastly, since a viral glycoprotein must be provided in
trans for every production, this system is not susceptible to mutations over several
passages and is not dependent on repeated, arduous rescue attempts for the study
of naturally occurring spike mutants or chimeric spike glycoproteins. These studies
may prove beneficial as we consider naturally occurring spike mutations—
described on platforms such as GISAID—and strive to understand their influence on
viral entry kinetics or their influence on escape from antibody neutralization.
In sum, we present detailed and optimized protocols for the production of a BSL2-
safe VSVDG-rLuc pseudoparticle and use it to interrogate viral entry. More importantly,
we present several resources that we believe will be invaluable during this global
pandemic. This includes cell lines (particularly 293T-ACE21TMPRSS2 and Vero-CCL81-
TMPRSS2 cells) and CoV2pp that are ready to use out of the box for mechanistic stud-
ies of viral entry or to screen inhibitors of viral entry. Our findings, resources, and pro-
posed guidelines have implications for standardizing viral neutralization assays, with
particular importance for screening therapeutic monoclonal antibodies, vaccine effi-
cacy, and convalescent-phase sera.
MATERIALS ANDMETHODS
Plasmids.
 SARS-CoV-2 spike is in a pCAGG backbone and expresses the codon-optimized Wuhan-Hu-1 isolate
(NCBI accession no. NC_045512.2).
 SARS-CoV-2 sRBD (NCBI GenBank accession no. MT380724.1 from the Krammer lab) is in a pCAGG
backbone and expresses the codon-optimized sequence from the Wuhan-Hu-1 isolate. The sRBD-
His, used for neutralization studies, was generated from this construct.
 VSV-G is in a pCAGG backbone and expresses wild-type Indiana strain VSV-G (Genbank accession
no. ACK77583.1).
 ACE2 packaging construct (GeneCopoeia; catalog [cat.] no. EX-U1285-Lv105) uses a cytomegalovirus
(CMV) promoter to express ACE2 and bears a puromycin selection marker in the integrating cassette.
 The TMPRSS2 packaging construct (GeneCopoeia; cat. no. EX-Z7591-Lv197) uses a CMV promoter
to express TMPRSS2 and bears a blasticidin selection marker in the integrating cassette.
 The psPAX2 2nd-generation lentiviral packaging plasmid (Addgene 12259) expresses HIV-1 Gag,
Pol, and Pro proteins.
 The NiV-RBP is in a pCAGG backbone and expresses the hemagglutinin (HA)-tagged, codon-
optimized NiV receptor binding protein.
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All plasmids listed here are ampicillin resistant. These constructs were transformed into stellar competent
cells, grown in bacterial growth media containing carbenicillin, prepared using Invitrogen’s midiprep kit, and
sequence verified prior to use for experiments.
Maintenance and generation of cell lines. Vero-CCL81 and 293T cells were cultured in DMEM with
10% heat-inactivated FBS at 37°C with 5% CO2. VSV-G-pseudotyped lentiviruses packaging ACE2 or
TMPRSS2 expression constructs were generated by using Bio-T (Bioland; B01-01) to transfect 293T cells
with the second-generation lentiviral packaging plasmid (Addgene; 12259) pCAGG-VSV-G and the
desired expression construct (i.e., ACE2 or TMPRSS2). The medium was changed the next morning. Viral
supernatant was collected 48 h posttransfection, clarified by centrifugation at 4,000 rpm for 5 min, and
aliquoted prior to storage at 280°C. Vero-CCL81 and 293T cells were transduced in a 6-well plate with
the prepared lentiviral constructs. Two days after transduction, these cells were expanded into a 10-cm
plate and placed under selection with puromycin (for ACE2-transduced cells) or blasticidin (for
TMPRSS2-transduced cells). 293T and Vero-CCL81 cells were selected with 2 and 10mg/ml of puromycin,
respectively. For blasticidin, 293T cells were selected with 5mg/ml and Vero-CCL81 cells were selected
with 15mg/ml. To generate ACE2- and TMPRSS2-expressing 293T cells, 293T-ACE2 cells were transduced
with VSV-G-pseudotyped lentivirus-packaged TMPRSS2. These cells were subsequently selected with
5mg/ml blasticidin. Low-passage-number stocks of each cell line generated were immediately frozen
down using Bambanker (Fisher Scientific; NC9582225). Single-cell, isogenic clones were isolated via serial
dilution in a 96-well plate. Wells with only a single cell were grown up and eventually expanded while
under selection.
Pseudovirus production and titering.We provide detailed production and titering protocols in the
supplementary text (Text S1). Briefly, 293T producer cells were transfected to overexpress SARS-CoV-
2 or VSV-G glycoproteins. For background entry with particles lacking a viral surface glycoprotein,
the pCAGG empty vector was transfected into 293T cells. Approximately 8 h posttransfection, cells
were infected with the VSVDG-rLuc reporter virus for 2 h and then washed with Dulbecco’s phos-
phate-buffered saline (DPBS). Two days postinfection, supernatants were collected and clarified by
centrifugation at 1,250 rpm for 5 min. For trypsin-treated CoV2pp, a small batch of particles was first
treated with TPCK-treated trypsin (Sigma-Aldrich; T1426-1G) at room temperature for 15 min prior
to inhibition with soybean trypsin inhibitor (SBTI) (Fisher Scientific; 17075029). Subsequently, the
rest of the CoV2pp were trypsin treated. All particles were aliquoted prior to storage at 280°C to
avoid multiple freeze-thaws.
To titer these pseudoviruses, 20,000 Vero-CCL81 cells were seeded in a 96-well plate 20 to 24 h
prior to infection. Single aliquots of BALDpp, CoV2pp, and VSV-Gpp were used for infections, and
titrations were performed in technical triplicates. At 18 to 22 h postinfection, the infected cells
were washed with DPBS, lysed with passive lysis buffer, and processed for detection of Renilla lucif-
erase. A Cytation3 apparatus (BioTek) was used to read luminescence. Additional details can be
found in Text S1.
Collection of producer cells and concentration of pseudotyped particles. Cell lysates were col-
lected from producer cells with 10mM EDTA in DPBS. Cells were subsequently lysed with radioimmuno-
precipitation assay (RIPA) buffer (Thermo Scientific; 89900) containing protease inhibitor (Thermo
Scientific; 87785) for 30 min on ice. Lysates were centrifuged at 25,000 g for 30 min at 4°C, and the
supernatants were collected and stored at 280°C. Total protein concentrations were determined by the
Bradford assay. For viral pseudoparticles, 10ml of designated viral particles was concentrated via a 20%
sucrose cushion (20% sucrose in DPBS), an Amicon Ultra centrifugal filter (100-kDa cutoff, UFC910024;
Millipore Sigma), or polyethylene glycol (PEG) precipitation (Abcam; ab102538). Concentrated viral par-
ticles were resuspended in 300 ml of PBS or Opti-MEM for further analysis.
Western blots. All protein samples were run under reduced conditions by dilution in 6 SDS con-
taining dithiothreitol (DTT) and 5% beta-mercaptoethanol (Fisher Scientific; ICN19483425). The protein
was subsequently incubated in a heating block at 95°C for 15 min, run on a 4 to 15% SDS-PAGE gel, and
transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad). Membranes were blocked with
phosphate-buffered saline blocking buffer (LI-COR; 927-700001) and then probed with the following
antibodies. Antibodies against SARS-CoV2 (2B3E5 from Thomas Moran and GTX632604 from GeneTex),
ACE2 (66699-1-Ig from Proteintech and Rb ab108252 from Abcam), VSV-G (A00199 from GenScript),
VSV-M (EB0011 from Kerafast), anti-HA (NB600-363 from Novus), and CoX IV (926-42214 from LI-COR)
were used. For secondary staining, membranes were washed and incubated with the appropriate Alexa
Fluor 647-conjugated anti-mouse antibody or Alexa Fluor 647-conjugated anti-rabbit antibody. Alexa
Fluor 647 was detected using the ChemiDoc MP imaging system (Bio-Rad). Relative ACE2 or TMPRSS2
abundance was calculated by first normalizing abundance relative to GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase) expression and then normalization to wild-type expression.
RNA extraction and qPCR for ACE2 and TMPRSS2 expression. Total RNA was extracted from cells
using a Direct-zol RNA miniprep kit (Zymo Research; R2051), and reverse transcription (RT) was performed
with the Tetro cDNA synthesis kit (Bioline; BIO-65043) and random hexamers. RT-PCR was performed with the
SensiFAST SYBR and fluorescein kit (Bioline; BIO-96005). For qPCRs, hypoxanthine phosphoribosyltransferase
(HPRT) forward (59-ATTGTAATGACCAGTCAACAGGG-39) and reverse (59-GCATTGTTTTGCCAGTGTCAA-39)
primers, ACE2 forward (59-GGCCGAGAAGTTCTTTGTATCT-39) and reverse (59-CCCAACTATCTCTCGCTTCATC-39)
primers, and TMPRSS2 forward (59-CCATGGATACCAACCGGAAA-39) and reverse (59-GGATGAAGTTTGGTCC
GTAGAG-39) primers were utilized. Samples were read on the CFX96 Touch real-time PCR detection system
(Bio-Rad). For qPCR, forward and reverse primers were utilized. The qPCR was performed in duplicates for
each sample, and results were calculated using 2–DDCT, where CT is threshold cycle, with normalization to the
HPRT housekeeping gene control and further normalization to the 293T parental cells.
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Serum acquisition. All patient sera were acquired after approval by the respective institutional
review boards (IRBs) and/or equivalent oversight bodies (Bioethics Committee, Independent Ethics
Committee), as follows: (i) the Mount Sinai Hospital IRB (New York, NY, USA), (ii) the Louisiana State
University Health Sciences Center—Shreveport (LSUHS, LA, USA), and (iii) the Fundacion Instituto Leloir-
CONICET, Universidad Nacional de San Martin, Laboratorio Lemos SRL, Universidad de Buenos Aires
(COVIDAR Argentina Consortium, Buenos Aires, Argentina). Samples were deidentified at the source
institutions or by the respective principal investigators (PIs) of the IRB-approved protocols for sample
collection before analyses performed in this study. All necessary patient/participant consent has been
obtained, and the appropriate institutional forms have been archived.
ELISAs and live-virus neutralization. Spike ELISAs for patient sera from the Krammer lab were per-
formed in a clinical setting using the two-step protocol previously published (Mount Sinai Hospital).
Briefly, this involves screening patient sera (at a 1:50 dilution) with the sRBD; samples determined to be
positive were further screened at 5 dilutions for reactivity to the spike ectodomain. All 36 samples were
screened in this manner, but a subset of 15 samples were further screened for IgG and IgM antibodies
binding to the spike ectodomain. The protocol from Stadlbauer et al. (106) was modified slightly to start
from a 1:300 and end at a 1:24,300 dilution of serum. IgG and IgM antibodies were detected with sec-
ondary antibodies conjugated to horseradish peroxidase (HRP) (Millipore AP101P for anti-human IgG
and Invitrogen A18841 for anti-human IgM). Background was subtracted from the OD values, samples
were determined to be positive if their ODs were $3-fold over that of the negative control, and the AUC
was calculated in PRISM. ELISAs performed by the LSUHS group utilized the sRBD with a 1:50 dilution of
patient serum to screen all samples, followed by use of the spike ectodomain with patient sera at a
1:100 dilution. Background-subtracted OD values are reported for both sets of ELISAs. ELISAs performed
by the COVIDAR group utilized a mixture of the sRBD and the spike ectodomain for samples serially
diluted from 1:50 to 1:6,400. AUCs were calculated as described above.
All live-virus neutralizations were performed at biosafety level 3 (BSL3) using the USA-WA/2020 iso-
late of SARS-CoV-2 as described by Amanat et al. (73). Briefly, ;600 50% tissue culture infective doses
(TCID50s) of virus were incubated with a serial dilution of patient sera for 1 h at 37°C prior to infection of
Vero-E6 cells. Forty-eight hours postinfection, cells were fixed in 10% paraformaldehyde (PFA) and
stained with mouse anti-SARS-CoV nucleoprotein antibody. This was subsequently detected by the addi-
tion of HRP-conjugated goat anti-mouse IgG and Sigmafast OPD. The BioTek Synergy 4 plate reader was
used to measure the OD at 490 nm (OD490), which was subsequently used to calculate microneutraliza-
tion (MN) titers. The samples with live-virus MN titers were a part of a larger study by Krammer and col-
leagues looking at the longitudinal dynamics of the humoral immune response. This study was recently
posted on medRxiv (35). We obtained permission from the authors to utilize a random subset of serum
samples from their study and their associated MN titers for validation studies with our CoV2pp-based vi-
rus neutralization assay (VNA).
Neutralization studies with patient sera, the soluble RBD, or nafamostat-mesylate. Deidentified
sera were obtained with IRB approval to use for research purposes. Unless otherwise noted, all patient
sera were heat inactivated at 56°C for 30 min and serially diluted in DMEMplus 10% FCS when we per-
formed VNAs. For groups receiving our CoV2pp, we recommended titrating our stocks first to determine
the linear dynamic range that would be useful for VNAs done in their labs. As a quality control, we send
out only CoV2pp stocks that give signal/noise ratios of at least 100-fold over that of BALDpp when
diluted 4-fold in a 100-ml total infection volume in a 96-well plate format. For the VNAs performed in our
lab (ISMMS-1), a pretitrated amount of pseudotyped particles (diluted to give approximately 105 RLUs)
was incubated with a 4-fold serial dilution of patient sera for 30 min at room temperature prior to infec-
tion of Vero-CCL81 cells seeded the previous day. For sRBD or nafamostat inhibition, a pretitrated
amount of pseudotyped particle dilution was mixed with the protein or compound and added to cells
immediately after. Approximately 20 h postinfection, cells were processed for the detection of luciferase
activity as described above. Our recommendations to generate a robust neutralization curve were to do
an 8-point serial dilution curve, with each point done in triplicate. Raw luminometry data were obtained
from labs that volunteered VNA results from at least 12 patient samples and analyzed as indicated
below.
Method modifications from the three contributing labs are as follows. Serum neutralizations by
LSUHS (J. P. Kamil and S. S. Ivanov) were performed by first diluting the serum 4-fold in a 100-ml total
volume and then diluting it via a 3-fold serial dilution. Cell lysates were transferred to a white-walled 96-
well plate, and then the Promega Renilla luciferase assay kit was utilized to detect luciferase. Plates were
read on a Tecan Spark plate reader by collecting total luminescence signal for 10 s. ISMMS-2 (C. E. Hioe)
began neutralizations at a 10-fold dilution and proceeded with a 4-fold serial dilution. Plates were read
on a black-walled 96-well plate using the Renilla Glo substrate (Promega; E2720), with a 1-s signal inte-
gration time. COVID-19 samples were provided to ISMMS-2 by the Clinical Pathology Laboratory at
ISMMS or from an IRB-approved study at the James J. Peters VA Medical Center. COVIDAR (A. V.
Gamarnik) began at either an 8-fold or a 16-fold dilution and then continued with either a 3-fold or a 2-
fold serial dilution, respectively. White, F-bottom Lumitrac plates (Greiner; 655074) were read via the
GloMax Navigator microplate luminometer (Promega; GM200) using the ONE-Glo luciferase assay system
(Promega; E6110).
IC calculations and other R packages used. Relative inhibitory concentration (IC) values were calcu-
lated for all patient serum samples by modeling a 4-parameter logistic regression with drm in the R drc
package (114). For examples, a relative inhibitory concentration of 50% (IC50) is calculated as the midway
point between the upper and lower plateaus of the curve. The absolute inhibitory concentration (absIC)
was calculated as the corresponding point between the 0% and 100% assay controls. For example, the
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absIC50 is the point at which the curve matches inhibition equal to exactly 50% of the 100% assay con-
trol relative to the assay minimum (0%) (115). As a result, serum samples that are nonneutralizing or
minimally neutralizing may have lower plateaus, indicating that they cannot reach certain absolute in-
hibitory concentrations, such as an absIC90 or absIC99. R was also used to generate the heatmaps pre-
sented in Fig. 4B and Fig. 5A as well as the plots in Fig. 4D and 5C and Fig. S7.
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